Neoangiogenesis control in oncology: mechanisms and prospects of practical application

Control over angiogenesis is a source of interest and object of studies for medical professionals of various specialties. Angiogenesis is a key component of malignant growth pathogenesis. The inhibition of this process may be used in the treatment of malignant neoplasms and their metastases, as well as benign tumors. In spite of tumor cells unique ability to cope with hypoxia and nutrients deficiency, they are however sooner or later experiencing need in adequate oxygen and glucose supply. Evidently to overcome the limitations of diffusion range fast-growing neoplasm needs to boost production of various proangiogenic factors that induce and stimulate growth of new blood vessels in peritumorous area as well as in the tumor itself. In spite of a large volume of studies the use of anti-angiogenic drugs in Oncology till nowadays is limited and in most of the cases is of empiric nature. Some of the researchers point out target anti-angiogenic therapy low effectivity with simultaneous increase of chemiotherapy in case of some oncologic ailments, shrinking of relapse-free period and increase of neoplasms' development and their invasive and metastatic potential. These problems require more profound investigation. The nature of interrelations between the tumor and blood vessels is complicated and the activity of neoangiogenesis affects the tumor growth to the same extent as the tumor affects angiogenesis. Nowadays we continue to amass data on this problem as well as find new versions of its interpretation, therefore one should soon expect a breakthrough in comprehension of tumor-angiogenesis correlation principles.